ClinicalTrials.gg
RecruitingNCT06491043Updated Jul 8, 2024

Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells

A Phase 2 interventional study of UMC119-06-05 in Chronic Obstructive Pulmonary Disease, sponsored by Meribank Biotech Co., Ltd.. Recruiting at 2 sites in Taiwan. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Meribank Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan — 28 open to participants now, 30 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Taiwan.

Planned enrollment
72nd of 124
90 · median 139
Started
2024
with 9 others
Phase 2
11 of 158
2 open now
Primary completion
2026-12
later than 5 of 29 live
Registered
130th of 158
by date

Among the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, this one is the 72nd largest by planned enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 5 of the 29 other live ones, and was the 130th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

28 of the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, or all of them as a file.
02

Study summary

This phase II study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of UMC119-06-05 compared to placebo in treating subjects with moderate to severe COPD. Eligible subjects will receive a single-dose IV infusion of UMC119-06-05 or placebo.

Read the detailed description

Patients with chronic obstructive pulmonary disease (COPD) are characterized with airflow limitation and chronic inflammation, which is caused by cigarette smoking, noxious particles or gases. These inhaled irritants will induce inflammation, emphysema and fibrosis though chronic exposure. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators and corticosteroids. Although current clinical treatment strategies can improve and stabilize COPD states and quality of life, none of them are able to modify the progressive decline in lung function, meaning it gradually gets worse over time. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of COPD in adult patients is of urgent need. Among the more innovative, experimental therapies, mesenchymal stromal cells are proposed as a novel therapy with potential in treatment of COPD. This clinical trial is a phase II study. It is a randomized, placebo-controlled, double-blind study. Eligible subjects will be randomized to one of the three groups: placebo control, low-dose UMC119-06-05 treatment, or high-dose UMC119-06-05 treatment. Subjects will receive a single-dose IV infusion to evaluate the efficacy and long-term safety of UMC119-06-05 with moderate to severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between ≥40 and ≤80 years of age, of either sex and of any race.
  2. With diagnosis of based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.
  3. Has a post-bronchodilator /FVC ratio \<0.70.
  4. Has a post-bronchodilator FEV1 predicted value ≥30% and \<80%.
  5. With a score ≥2 in the mMRC dyspnea scale.
  6. With a score ≥10 in the COPD Assessment Test (CAT).
  7. With a body weight ≥40 to ≤90 kg.
  8. The disease status of COPD has been stable as determined by the investigator, and the standard treatment for COPD was not adjusted within 3 months prior to screening.
  9. Is a current or ex-smoker, with a cigarette smoking history of ≥10 years or >10 pack-years.
  10. Women of should have a negative urine pregnancy test at screening, UNLESS they meet the following criteria:

(1): 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with the serum follicle stimulating hormone (FSH) level >40 mIU/mL, OR; (2)6 weeks post-surgical bilateral oophorectomy with or without hysterectomy 11.Heterosexually active subjects must agree to use a double barrier method of (or must have been surgically sterilized/post-menopausal) and not to donate sperms/eggs during the study.

12.Willing to provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Has evidence of active or prior history of active malignancy that has not been in complete remission for at least 5 years prior to screening.
  2. Diagnosed with asthma or other lung disease other than (e.g., restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer).
  3. Has initiated pulmonary rehabilitation (e.g., exercise training) within 3 months prior to screening which, in the opinion of the Principal Investigator (PI), may affect the study's results.
  4. Has documented history of uncontrolled heart failure.
  5. Has pulmonary hypertension due to left heart condition.
  6. Has atrial fibrillation or significant congenital heart defect/disease.
  7. Has had a moderate or severe exacerbation of COPD (defined by GOLD standard) or has required mechanical ventilation (not including continuous positive airway pressure [CPAP]) within 30 days prior to screening.
  8. Is hospitalized at screening.
  9. With current active infection including pulmonary infection, systemic infection, or severe local infections.
  10. Have the following conditions in laboratory tests at screening:

    1. >2 × (ULN) for (ALT) or aspartate aminotransferase (AST); or
    2. Estimated (eGFR) \<60 mL/min/1.73m2; or
    3. White blood cells (WBC) \<3.6 × 103/μL; or
    4. counts \<150 × 103/μL; or
    5. \<10 g/dL; or
    6. Spot urine albumin-creatinine ratio (UACR) ≥30 mg/g; or
    7. Clinically significant hematuria or proteinuria deemed by the study investigator.
  11. With known stage ≥3 chronic kidney disease.
  12. Received systemic or other , immunomodulators, cytotoxic agents, chemotherapy, radiation therapy, or other cell therapies within 28 days or 5 half-lives, whichever is longer, prior to screening.
  13. With known alpha-1 antitrypsin deficiency.
  14. With known allergy or to any component of the product (IP) formulation (normal saline and human serum albumin [HSA]).
  15. With a known history of drug-related anaphylaxis or other severe allergic reactions to drug.

    Note: "Severe" is defined as (CTCAE) v5.0 Grade 3 or greater.

  16. Underwent major surgery (body organs that require anesthesia, such as tumor removal, open chest, heart surgery, abdominal surgery, intracranial surgery, or normal surgery for more than 3 hours, etc.) within 30 days prior to screening.
  17. With known infection or immunocompromised.
  18. With a known history of alcohol abuse or drug abuse within 5 years prior to screening.
  19. Participating in another clinical study of new investigational therapies or have received an investigational therapy within 3 months prior to screening.
  20. Pregnant (or plan to become pregnant within 3 months after study treatment) or lactating.
  21. Has a of \<6 months.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    normal saline, 4% human serum albumin

    Other: UMC119-06-05

  • Experimental
    low-dose UMC119-06-05 treatment

    normal saline, 4% human serum albumin, 1×10\^8 cells/subject

    Other: UMC119-06-05

  • Experimental
    high-dose UMC119-06-05 treatment

    normal saline, 4% human serum albumin, 2×10\^8 cells/subject

    Other: UMC119-06-05

Interventions

  • OtherUMC119-06-05

    Human Umbilical Cord Derived-Mesenchymal Stem Cells

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities. 2.Incidence of related TEAEs and serious adverse events (SAEs) 3.Incidence of withdrawals due to adverse events (AEs) 4.Change/shift from baseline in laboratory tests 5.Change from baseline in vital signs 6.Shift from baseline in ECG results 7.Shift from baseline in physical examination results

    Time frame: From Baseline to Day 90]

  2. Incidence of related TEAEs and serious adverse events (SAEs)

    Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities. 2.Incidence of related TEAEs and serious adverse events (SAEs) 3.Incidence of withdrawals due to adverse events (AEs) 4.Change/shift from baseline in laboratory tests 5.Change from baseline in vital signs 6.Shift from baseline in ECG results 7.Shift from baseline in physical examination results

    Time frame: through the study

  3. Incidence of withdrawals due to adverse events (AEs)

    AE incidence

    Time frame: through the study

  4. Change/shift from baseline in laboratory tests

    laboratory tests

    Time frame: Baseline, 2 hours (h), Days 3, 7, 14, 28, 90

  5. Change from baseline in vital signs

    measure vital signs

    Time frame: Baseline, 0 minute, 2 h, Days 3, 7, 14, 28, 90

  6. shift from baseline in ECG results

    ECG check

    Time frame: Baseline, 2 h, Day 14

  7. Shift from baseline in physical examination results

    physical examination

    Time frame: Baseline, 2 h, Days 3, 7, and 14

Secondary outcomes

  1. Mean change from baseline in forced vital capacity (FVC)

    Respiratory functions (FVC) 2.Mean change from baseline in forced expiratory volume in one second (FEV1) 3.Mean change from baseline in FEV1/FVC ratio 4.Mean change from baseline in 6-minute walk test (6-MWT) 5.Mean change from baseline in St. George's Respiratory Questionnaire (SGRQ) score 6.Shift from baseline in modified Medical Research Council (mMRC) dyspnea scale 7.Incidence, frequency, and severity of COPD exacerbations 8.Time to first COPD exacerbation 9.Mean change or shift from baseline in Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index 10.The number of times that rescue medication is used

    Time frame: Baseline, Days 28, 90, 180, 270, 360

  2. Mean change from baseline in forced expiratory volume in one second (FEV1)

    Respiratory functions (FEV1)

    Time frame: Baseline, Days 28, 90, 180, 270, 360

  3. Mean change from baseline in FEV1/FVC ratio

    Respiratory functions (FEV1/FVC)

    Time frame: Baseline, Days 28, 90, 180, 270, 360

  4. Mean change from baseline in 6-minute walk test

    measure 6 minute walk distance

    Time frame: Baseline, Days 28, 90, 180, 270, 360

  5. Mean change from baseline in St. George's Respiratory Questionnaire (SGRQ) score

    Georges Respiratory Questionnaire has scores range from 0 to 100, with higher scores indicating more limitations

    Time frame: Baseline, Days 28, 90, 180, 270, 360

  6. Shift from baseline in modified Medical Research Council (mMRC) dyspnea scale

    mMRC dyspnea scale

    Time frame: Baseline, Days 28, 90, 180, 270, 360

  7. Incidence, frequency, and severity of COPD exacerbations

    assess severity of COPD

    Time frame: through the study

  8. Time to first COPD exacerbation

    assess severity and exacerbation

    Time frame: through the study

  9. 9. Mean change or shift from baseline in Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index

    BODE index

    Time frame: baseline to Days 28, 90, 180, 270, 360

  10. he number of times that rescue medication is used

    times of rescue medication

    Time frame: through the study

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 30 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2024
First posted
Jul 8, 2024
StartActual
Jun 11, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06491043
Lead sponsor
Meribank Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jul 8, 2024
Start date
Jun 11, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jul 8, 2024

Study contacts

Ray Chang, Ph.D.
Contact
ray.chang@meribank.com.tw
+886-2-8978-7777 ext. 19915
Joseph Chen, Ph.D.
Contact
joseph.chen@meribank.com.tw
+886-2-8978-7777 ext. 19905

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion